1.Explore the Optimal Resolvent of Medical Needs and Mental Health for Patients with Lung Cancer during Epidemic Novel Coronavirus Pneumonia.
Haiyan XU ; Ke YANG ; Guangjian YANG ; Lu YANG ; Yuling MI ; Xiaohong CUI ; Min YANG ; Dan WANG ; Yan WANG
Chinese Journal of Lung Cancer 2020;23(4):247-254
BACKGROUND:
With the rapid spread of novel coronavirus pneumonia (NCP) worldwide and the escalation of prevention and control efforts, the routine medical needs of patients have been restricted. The aims were to investigate medical needs of lung cancer patients and their mental health status during the epidemic periods, so as to provide rational recommendations for subsequent diagnosis and treatment.
METHODS:
The questionnaire was sent in the form of an electronic questionnaire at 7am on 4th, March, 2020, until 7am 6th, March, 2020, 368 questionnaires were recollected from 25 provinces (autonomous regions/municipalities) in 48 h.
RESULTS:
Of the 368 patients, 18 patients were excluded as they didn't receive anti-tumor treatment, and 350 patients were included in the final analysis. 229 cases were treated with oral targeted drugs, and 121 cases were treated with chemotherapy or immunotherapy. 41.3% of patients treated with intravenous chemotherapy or immunotherapy experienced treatment discontinuation, and the proportion of treatment discontinuation in chemotherapy or immunotherapy was higher than those treated with oral targeted drugs (21.0%). Whether oral targeted drugs or intravenous chemotherapy or immunotherapy, more than 60% of patients experienced delays in imaging examinations. Nearly one third of patients developed new symptoms or exacerbation of existing symptoms. 26.6%-28.9% of patients have changed their treatment plans through online consultation. During novel coronavirus pneumonia, 40%-75% of lung cancer patients have mental health problems, and more than 95% of patients support government's prevention and control measures.
CONCLUSIONS
During the emergence of NCP, the medical needs of patients with lung cancer have not been enough, especially those who discontinued chemotherapy or immunotherapy. When medical institution resumes work, priority should be given to them. At the same time, mental health problems of patients should be valued and resolved timely.
Adult
;
Aged
;
Antineoplastic Agents
;
therapeutic use
;
Betacoronavirus
;
physiology
;
China
;
epidemiology
;
Coronavirus Infections
;
epidemiology
;
virology
;
Female
;
Humans
;
Lung Neoplasms
;
drug therapy
;
psychology
;
Male
;
Middle Aged
;
Pandemics
;
Pneumonia
;
epidemiology
;
virology
;
Pneumonia, Viral
;
epidemiology
;
virology
;
Retrospective Studies
2.Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice.
Jinliang WANG ; Lei SHUAI ; Chong WANG ; Renqiang LIU ; Xijun HE ; Xianfeng ZHANG ; Ziruo SUN ; Dan SHAN ; Jinying GE ; Xijun WANG ; Ronghong HUA ; Gongxun ZHONG ; Zhiyuan WEN ; Zhigao BU
Protein & Cell 2020;11(10):776-782
Adaptation, Physiological
;
Adenosine Monophosphate
;
administration & dosage
;
analogs & derivatives
;
pharmacology
;
therapeutic use
;
Administration, Intranasal
;
Alanine
;
administration & dosage
;
analogs & derivatives
;
pharmacology
;
therapeutic use
;
Animals
;
Betacoronavirus
;
genetics
;
physiology
;
Chlorocebus aethiops
;
Coronavirus Infections
;
drug therapy
;
virology
;
Disease Models, Animal
;
Female
;
Host Specificity
;
genetics
;
Lung
;
pathology
;
virology
;
Male
;
Mice
;
Mice, Inbred BALB C
;
Mice, Inbred C57BL
;
Mutation, Missense
;
Nasal Mucosa
;
virology
;
Pandemics
;
Pneumonia, Viral
;
drug therapy
;
virology
;
RNA, Viral
;
administration & dosage
;
genetics
;
Turbinates
;
virology
;
Vero Cells
;
Viral Load
;
Virus Replication
3.Narrative synthesis of psychological and coping responses towards emerging infectious disease outbreaks in the general population: practical considerations for the COVID-19 pandemic.
Qian Hui CHEW ; Ker Chiah WEI ; Shawn VASOO ; Hong Choon CHUA ; Kang SIM
Singapore medical journal 2020;61(7):350-356
INTRODUCTION:
Emerging infectious disease outbreaks, such as the present coronavirus disease 2019 (COVID-19) pandemic, often have a psychological impact on the well-being of the general population, including survivors and caregivers. Our study aimed to synthesise extant literature regarding the combined psychological responses and coping methods used by the general population in past outbreaks.
METHODS:
We conducted a narrative synthesis of the published literature over the last two decades with a quality appraisal of included articles that reported both psychological responses and coping strategies within infectious disease outbreaks.
RESULTS:
A total of 144 papers were identified from the search, 24 of which were included in the review. Overall, 18 studies examined the psychosocial responses of the general population towards the severe acute respiratory syndrome epidemic, four studies focused on the Ebola epidemic and two studies covered the H1N1 outbreak. Common themes in psychological responses included anxiety/fears, depression, anger, guilt, grief and loss, post-traumatic stress and stigmatisation, but also a greater sense of empowerment and compassion towards others. Coping strategies adopted included problem-focused coping (seeking alternatives, self- and other-preservation), seeking social support, avoidance, and positive appraisal of the situation.
CONCLUSION
Amid the range of psychosocial responses seen in past infectious disease outbreaks, practical considerations for the current COVID-19 pandemic need to focus on the individual in the context of the larger social environment, with an emphasis on raising awareness of the range of possible psychosocial responses, access to psychological help, self-care, empowering self-support groups and sustained engagement with updated, reliable information about the outbreak.
Adaptation, Psychological
;
physiology
;
Betacoronavirus
;
Coronavirus Infections
;
epidemiology
;
psychology
;
Health Personnel
;
psychology
;
Humans
;
Mental Health
;
Pandemics
;
Pneumonia, Viral
;
epidemiology
;
psychology
;
Stress, Psychological
;
epidemiology
;
etiology
;
psychology
4.Cross-reaction of Sera from COVID-19 Patients with SARS-CoV Assays.
Wei Yee WAN ; Siew Hoon LIM ; Eng Hong SENG
Annals of the Academy of Medicine, Singapore 2020;49(7):523-526
Antibodies, Viral
;
physiology
;
Betacoronavirus
;
physiology
;
Clinical Laboratory Techniques
;
Coronavirus Infections
;
diagnosis
;
Cross Reactions
;
physiology
;
Enzyme-Linked Immunosorbent Assay
;
Fluorescent Antibody Technique, Indirect
;
Humans
;
Pandemics
;
Pneumonia, Viral
;
diagnosis
;
SARS Virus
;
physiology
8.Single-cell RNA sequencing data suggest a role for angiotensin-converting enzyme 2 in kidney impairment in patients infected with 2019-novel coronavirus.
Yi-Yao DENG ; Ying ZHENG ; Guang-Yan CAI ; Xiang-Mei CHEN ; Quan HONG
Chinese Medical Journal 2020;133(9):1129-1131
Acute Kidney Injury
;
etiology
;
Betacoronavirus
;
Coronavirus Infections
;
complications
;
Humans
;
Kidney
;
enzymology
;
Pandemics
;
Peptidyl-Dipeptidase A
;
physiology
;
Pneumonia, Viral
;
complications
;
Sequence Analysis, RNA
;
methods
;
Serine Endopeptidases
;
physiology
;
Single-Cell Analysis
;
methods
9.Replication and transmission mechanisms of highly pathogenic human coronaviruses.
Journal of Zhejiang University. Medical sciences 2020;49(1):324-339
The three known human highly pathogenic coronaviruses are severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus, (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Human highly pathogenic coronaviruses are composed of non-structural proteins, structural proteins and accessory proteins. Viral particles recognize host receptors via spike glycoprotein (S protein), enter host cells by membrane fusion, replicate in host cells through large replication-transcription complexes, and promote proliferation by interfering with and suppressing the host's immune response. Human highly pathogenic coronaviruses are hosted by humans and vertebrates. Viral particles are transmitted through droplets, contact and aerosols or likely through digestive tract, urine, eyes and other routes. This review discusses the mechanisms of proliferation and transmission of highly pathogenic human coronaviruses based on the results of existing research, providing basis for future study on interrupting the transmission and pathogenicity of human highly pathogenic coronaviruses.
Animals
;
Betacoronavirus
;
physiology
;
Coronavirus Infections
;
immunology
;
transmission
;
virology
;
Humans
;
Middle East Respiratory Syndrome Coronavirus
;
physiology
;
Pandemics
;
Pneumonia, Viral
;
immunology
;
transmission
;
virology
;
SARS Virus
;
physiology
;
Virus Replication
;
physiology
10.Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Rui XIONG ; Leike ZHANG ; Shiliang LI ; Yuan SUN ; Minyi DING ; Yong WANG ; Yongliang ZHAO ; Yan WU ; Weijuan SHANG ; Xiaming JIANG ; Jiwei SHAN ; Zihao SHEN ; Yi TONG ; Liuxin XU ; Yu CHEN ; Yingle LIU ; Gang ZOU ; Dimitri LAVILLETE ; Zhenjiang ZHAO ; Rui WANG ; Lili ZHU ; Gengfu XIAO ; Ke LAN ; Honglin LI ; Ke XU
Protein & Cell 2020;11(10):723-739
Emerging and re-emerging RNA viruses occasionally cause epidemics and pandemics worldwide, such as the on-going outbreak of the novel coronavirus SARS-CoV-2. Herein, we identified two potent inhibitors of human DHODH, S312 and S416, with favorable drug-likeness and pharmacokinetic profiles, which all showed broad-spectrum antiviral effects against various RNA viruses, including influenza A virus, Zika virus, Ebola virus, and particularly against SARS-CoV-2. Notably, S416 is reported to be the most potent inhibitor so far with an EC of 17 nmol/L and an SI value of 10,505.88 in infected cells. Our results are the first to validate that DHODH is an attractive host target through high antiviral efficacy in vivo and low virus replication in DHODH knock-out cells. This work demonstrates that both S312/S416 and old drugs (Leflunomide/Teriflunomide) with dual actions of antiviral and immuno-regulation may have clinical potentials to cure SARS-CoV-2 or other RNA viruses circulating worldwide, no matter such viruses are mutated or not.
Animals
;
Antiviral Agents
;
pharmacology
;
therapeutic use
;
Betacoronavirus
;
drug effects
;
physiology
;
Binding Sites
;
drug effects
;
Cell Line
;
Coronavirus Infections
;
drug therapy
;
virology
;
Crotonates
;
pharmacology
;
Cytokine Release Syndrome
;
drug therapy
;
Drug Evaluation, Preclinical
;
Gene Knockout Techniques
;
Humans
;
Influenza A virus
;
drug effects
;
Leflunomide
;
pharmacology
;
Mice
;
Mice, Inbred BALB C
;
Orthomyxoviridae Infections
;
drug therapy
;
Oseltamivir
;
therapeutic use
;
Oxidoreductases
;
antagonists & inhibitors
;
metabolism
;
Pandemics
;
Pneumonia, Viral
;
drug therapy
;
virology
;
Protein Binding
;
drug effects
;
Pyrimidines
;
biosynthesis
;
RNA Viruses
;
drug effects
;
physiology
;
Structure-Activity Relationship
;
Toluidines
;
pharmacology
;
Ubiquinone
;
metabolism
;
Virus Replication
;
drug effects

Result Analysis
Print
Save
E-mail